Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment

類似資料

• Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
  著者:: Raschi, Emanuel, 等
  出版事項: (2021)
• Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
  著者:: Raschi, Emanuel, 等
  出版事項: (2020)
• Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance
  著者:: Raschi, Emanuel, 等
  出版事項: (2020)
• Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
  著者:: Raschi, Emanuel, 等
  出版事項: (2019)
• Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
  著者:: Gatti, Milo, 等
  出版事項: (2021)